drugset
drugset / Trial / NCT02640989

Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military

NCT02640989 ↗

Phase 4 Completed 292 enrolled Center for Disease Prevention and Control of Beijing Military Region
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to assess the safety and immunogenicity of three seasonal trivalent influenza vaccines (TIVs)manufactured by Glaxosmith Kline (GSK), Beijing Sinovac Biotech (Sinovac) and Shenzhen Sanofi Pasteur (Pasteur) in Chinese healthy servicemen. Using imported GSK's TIV as control, to compare it with other two domestic TIVs in Chinese healthy servicemen.

Timeline

Start
2014-10
Primary completion
2014-10
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Anflu Vaccine 0.5 ml Intramuscular
Comparator Influenza Virus Vaccine Vaccine 0.5 ml Intramuscular

Indications

influenza